Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer
Prashant Changoer, Chunying Peng, Pepijn van Houten, Liesbeth van Emst, Janneke E W Walraven, Petronella B Ottevanger, Martin Jaeger, Romana T Netea-Maier · 2025
Read Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer by Prashant Changoer, Chunying Peng, Pepijn van Houten, Liesbeth van Emst, Janneke E W Walraven, Petronella B Ottevanger, Martin Jaeger, Romana T Netea-Maier (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717327.txt.
Description
Prashant Changoer and colleagues map immune shifts under a thyroid cancer drug, in work from 2025. Lenvatinib is approved for advanced thyroid cancer that is not of medullary type. Tumour inflammation helps drive this cancer, so immune effects of the drug matter for care design.
Blood came from treated and untreated patients plus a small before and after group. Treated patients had more lymphocytes and fewer neutrophils in blood counts. Protein profiles shifted for growth, attraction, and cell death signals in both groups. Lab exposed white cells made fewer key signals after drug contact in dishes. Tumour cells raised display and alarm proteins under the drug, which may aid immune attack.
Catalog record
| CREATOR | Prashant Changoer, Chunying Peng, Pepijn van Houten, Liesbeth van Emst, Janneke E W Walraven, Petronella B Ottevanger, Martin Jaeger, Romana T Netea-Maier |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |